Dimeric SSTR2 Radiopharmaceuticals for Higher Tumor Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing radiopharmaceuticals face challenges in selective targeting of somatostatin type 2 receptors (SSTR2) on tumors, with issues such as low compound yields, limited radiochemical stability, solubility, and increased off-target radiation damage due to insufficient retention at tumor sites, necessitating higher doses that exacerbate side effects.
Innovation Solution
Development of compounds comprising a sarcophagine chelator and two linker moieties for binding to SSTR2, which enhance tumor site retention and radiolytic stability, allowing for smaller doses of radionuclides to be administered while maintaining effective imaging and therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of radiopharmaceuticals are administered to increase treatment efficacy and imaging resolution, then the effectiveness of treatment and imaging is improved, but off-target radiation damage and side effects increase
Solution Approach 1:
The radiopharmaceutical is segmented into distinct functional modules: a SSTR2-targeting peptide moiety (e.g., octreotate) and a radionuclide-chelator complex. This segmentation allows the targeting component to selectively bind to tumor receptors while the radionuclide delivers therapeutic or imaging effects, improving tumor-to-background ratio and reducing off-target radiation exposure
Solution Approach 2:
A chelator molecule acts as an intermediary between the SSTR2-targeting peptide and the radionuclide. The chelator stabilizes the radionuclide while being conjugated to the targeting peptide, ensuring that the radionuclide is delivered specifically to tumor sites expressing SSTR2 receptors, thereby reducing systemic radiation exposure
2Reliability
If compounds are designed to improve tumor site retention, then treatment efficiency and imaging quality improve, but compound complexity and synthesis difficulty increase
Solution Approach 1:
The radiopharmaceutical compound is designed with multi-functionality: the peptide moiety provides selective SSTR2 targeting, the chelator ensures radionuclide stability, and the overall structure enables both diagnostic imaging and therapeutic functions. This universal design allows a single compound to achieve multiple objectives (targeting, retention, imaging, therapy) without requiring separate complex systems
Solution Approach 2:
The radiopharmaceutical is a composite molecule combining organic peptide components (for biological targeting and recognition) with inorganic radionuclide components (for radiation delivery). This composite structure integrates the advantages of both material types: the peptide provides selective tumor binding and retention, while the radionuclide-chelator complex provides stable radiation emission for imaging and therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate improved binding and retention at SSTR2-expressing tumors, reducing off-target radiation damage and side effects, enabling more efficient treatment and imaging with lower doses.
Implementation Method 1
compounds comprise a metal chelator and fragments that are capable of binding to somatostatin receptors
Implementation Method 2
coordinate a radioisotope, they must also display sufficient radiolytic stability
Implementation Method 3
Binding at these receptors may inhibit growth of the tumour
Implementation Method 4
moieties that are capable of binding to SSTR2
Data Source
AI summary
The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to type 2 somatostatin receptors, compositions thereof and uses thereof in methods of treatment.